BROOKLYN, New York–(BUSINESS WIRE)–Carrot (formerly Virtual Field), the most widely used VR testing and diagnostic platform in eye care, today announced an agreement to acquire GreenMan Vision, Inc., the company behind InSightVR. The deal will add in…
Author: Business Wire
Stuart Therapeutics Expands Pipeline with Corneal Wound Healing Program
STUART, Fla.–(BUSINESS WIRE)–Stuart Therapeutics Inc., a late-stage biopharmaceutical company developing a new class of therapeutics designed to treat eye diseases by repairing helical collagen, today announced it has submitted an investigational new…
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced posit…
Humana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027
LOUISVILLE, Ky.–(BUSINESS WIRE)–Humana Inc. (NYSE: HUM), a leading consumer healthcare company focused on helping people achieve their best health, today announced improved Star Ratings for 2027, highlighted by 95% of its Medicare Advantage members b…
STAAR Surgical Names Andrew Pilon as Vice President of Business Development
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointme…
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an ex…
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics et l'Hôpital National des 15-20 annoncent la publication dans le NEJM des résultats de l'essai de Phase 1/2 évaluant GS030 dans la rétinopathie pigmentaire au stade avancé
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des m…
GenSight Biologics publie sa situation de trésorerie au 30 septembre 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
GenSight Biologics Reports Cash Position as of September 30, 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today posit…
Inflammasome Therapeutics to Present New Phase 2 Analyses of K8 in Geographic Atrophy at AAO Retina Subspecialty Day
NEWTON, Mass.–(BUSINESS WIRE)–Inflammasome Therapeutics today announced that additional analyses from its Phase 2 study of Kamuvudine K8 in geographic atrophy will be presented at the American Academy of Ophthalmology (AAO) Retina Subspecialty Day in…
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release thir…
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigati…
Sightview Debuts New AI Scribe and AI Vision Verify at AAO 2026
TAMPA, Fla.–(BUSINESS WIRE)– #AIScribe–Sightview announced two AI offerings it will showcase at the American Academy of Ophthalmology’s (AAO) 2026 annual meeting, Oct. 9-12 in New Orleans.
Ray Therapeutics Celebrates 2026 Nobel Prize for Foundational Discoveries in Optogenetics
BERKELEY, Calif.–(BUSINESS WIRE)–Ray Therapeutics (RayTx) congratulates Drs. Karl Deisseroth, Peter Hegemann, and Georg Nagel on receiving the 2026 Nobel Prize in Physiology or Medicine for discoveries involving light-gated ion channels that helped l…
Science Corp. Announces Long-Term (36 Months) Results of PRIMA BCI Clinical Trial Showing Durable Vision Restoration in Blind Patients Suffering from Geographic Atrophy
ALAMEDA, Calif.–(BUSINESS WIRE)–Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced long-term (36 months) followup data from its pivotal PRIMAvera clinical trial (NCT04676854). The results were pres…
Sling Therapeutics to Present Data from Phase 2b/3 LIDS Trial of Oral IGF-1R Inhibitor Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium
ANN ARBOR, Mich.–(BUSINESS WIRE)–Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced that data from its Phase 2b/3 LI…
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The …
New 2026 Cell and Gene Therapy Report Charts the Path from Scientific Progress to Patient Access
IRVING, Texas–(BUSINESS WIRE)–InspiroGene™ by McKesson today announced the publication of its third annual 2026 Cell and Gene Therapy Report.